Novo Nordisk A/S (NOV.DE)
EUR 51.84
(-6.91%)
EUR 51.84
(-6.91%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 196.49 Billion DKK | 32.55% |
| 2022 | 19.57 Billion DKK | 26.02% |
| 2021 | 15.53 Billion DKK | 11.34% |
| 2020 | 13.94 Billion DKK | 3.38% |
| 2019 | 13.49 Billion EUR | 8.36% |
| 2018 | 12.45 Billion EUR | -0.82% |
| 2017 | 12.55 Billion EUR | -0.78% |
| 2016 | 12.65 Billion EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 57.78 Billion DKK | 4.24% |
| 2024 Q1 | 7.41 Billion DKK | -0.74% |
| 2023 FY | 25.94 Billion DKK | 32.55% |
| 2023 Q2 | 6.22 Billion DKK | 2.77% |
| 2023 Q3 | 6.55 Billion DKK | 5.4% |
| 2023 Q4 | 7.48 Billion DKK | 14.23% |
| 2023 Q1 | 6.05 Billion DKK | 13.35% |
| 2022 Q2 | 4.71 Billion EUR | -0.04% |
| 2022 FY | 19.57 Billion DKK | 26.02% |
| 2022 Q4 | 5.34 Billion EUR | 3.82% |
| 2022 Q3 | 5.14 Billion EUR | 9.02% |
| 2022 Q1 | 4.72 Billion EUR | 9.39% |
| 2021 FY | 15.53 Billion DKK | 11.34% |
| 2021 Q3 | 3.97 Billion EUR | 0.0% |
| 2021 Q4 | 4.31 Billion EUR | 8.55% |
| 2020 FY | 13.94 Billion DKK | 3.38% |
| 2019 FY | 13.49 Billion EUR | 8.36% |
| 2018 FY | 12.45 Billion EUR | -0.82% |
| 2017 FY | 12.55 Billion EUR | -0.78% |
| 2016 FY | 12.65 Billion EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| BioNTech SE | 3.21 Billion EUR | -6003.877% |
| CureVac N.V. | -70.6 Million EUR | 278391.412% |
| Biotest Aktiengesellschaft | 271.9 Million EUR | -72167.745% |
| Biotest Aktiengesellschaft | 271.9 Million EUR | -72167.745% |
| BRAIN Biotech AG | 30.12 Million EUR | -652233.842% |
| Formycon AG | 23.3 Million EUR | -843049.539% |
| Heidelberg Pharma AG | 6.6 Million EUR | -2974370.201% |
| Medigene AG | 4.39 Million EUR | -4474871.533% |